Cargando…
Closantel; a veterinary drug with potential severe morbidity in humans
BACKGROUND: Closantel is a halogenated salicylanilide with a potent anti parasitic activity. It is widely used in management of parasitic infestation in animals, but is contraindicated in humans. CASE PRESENTATION: A 34-year-old man with depression was referred to our center with progressive loss of...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5129234/ https://www.ncbi.nlm.nih.gov/pubmed/27899086 http://dx.doi.org/10.1186/s12886-016-0387-x |
_version_ | 1782470551927783424 |
---|---|
author | Tabatabaei, Seyed Ali Soleimani, Mohammad Mansouri, Mohammad Reza Mirshahi, Ahmad Inanlou, Bahman Abrishami, Mojtaba Pakrah, Ahmad Reza Masarat, Hamideh |
author_facet | Tabatabaei, Seyed Ali Soleimani, Mohammad Mansouri, Mohammad Reza Mirshahi, Ahmad Inanlou, Bahman Abrishami, Mojtaba Pakrah, Ahmad Reza Masarat, Hamideh |
author_sort | Tabatabaei, Seyed Ali |
collection | PubMed |
description | BACKGROUND: Closantel is a halogenated salicylanilide with a potent anti parasitic activity. It is widely used in management of parasitic infestation in animals, but is contraindicated in humans. CASE PRESENTATION: A 34-year-old man with depression was referred to our center with progressive loss of vision in both eyes 10 days after unintentional ingestion of three 500 mg tablets of Closantel. On fundus examination, left optic disc margin was blurred. His bilateral visual acuity was no light perception (NLP) despite prescribed IV erythropoietin injections 20,000 units daily for 3 days and 1gr intravenous methylprednisolone acetate for 3 days followed by 1 mg/kg oral prednisolone. On macular optical coherence tomography (OCT), a disruption in outer retina was observed. Electroretinogram and visual evoked potential tests showed visual pathway involvement. CONCLUSIONS: Destruction of neurosensory retina and visual pathways after accidental Closantel use is related to severe visual loss. This case alerts us about the destructive effect of this drug on humans even in low dosage which necessitates preventive efforts to reduce the chance of this morbid side effect. |
format | Online Article Text |
id | pubmed-5129234 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-51292342016-12-12 Closantel; a veterinary drug with potential severe morbidity in humans Tabatabaei, Seyed Ali Soleimani, Mohammad Mansouri, Mohammad Reza Mirshahi, Ahmad Inanlou, Bahman Abrishami, Mojtaba Pakrah, Ahmad Reza Masarat, Hamideh BMC Ophthalmol Case Report BACKGROUND: Closantel is a halogenated salicylanilide with a potent anti parasitic activity. It is widely used in management of parasitic infestation in animals, but is contraindicated in humans. CASE PRESENTATION: A 34-year-old man with depression was referred to our center with progressive loss of vision in both eyes 10 days after unintentional ingestion of three 500 mg tablets of Closantel. On fundus examination, left optic disc margin was blurred. His bilateral visual acuity was no light perception (NLP) despite prescribed IV erythropoietin injections 20,000 units daily for 3 days and 1gr intravenous methylprednisolone acetate for 3 days followed by 1 mg/kg oral prednisolone. On macular optical coherence tomography (OCT), a disruption in outer retina was observed. Electroretinogram and visual evoked potential tests showed visual pathway involvement. CONCLUSIONS: Destruction of neurosensory retina and visual pathways after accidental Closantel use is related to severe visual loss. This case alerts us about the destructive effect of this drug on humans even in low dosage which necessitates preventive efforts to reduce the chance of this morbid side effect. BioMed Central 2016-11-29 /pmc/articles/PMC5129234/ /pubmed/27899086 http://dx.doi.org/10.1186/s12886-016-0387-x Text en © The Author(s). 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Case Report Tabatabaei, Seyed Ali Soleimani, Mohammad Mansouri, Mohammad Reza Mirshahi, Ahmad Inanlou, Bahman Abrishami, Mojtaba Pakrah, Ahmad Reza Masarat, Hamideh Closantel; a veterinary drug with potential severe morbidity in humans |
title | Closantel; a veterinary drug with potential severe morbidity in humans |
title_full | Closantel; a veterinary drug with potential severe morbidity in humans |
title_fullStr | Closantel; a veterinary drug with potential severe morbidity in humans |
title_full_unstemmed | Closantel; a veterinary drug with potential severe morbidity in humans |
title_short | Closantel; a veterinary drug with potential severe morbidity in humans |
title_sort | closantel; a veterinary drug with potential severe morbidity in humans |
topic | Case Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5129234/ https://www.ncbi.nlm.nih.gov/pubmed/27899086 http://dx.doi.org/10.1186/s12886-016-0387-x |
work_keys_str_mv | AT tabatabaeiseyedali closantelaveterinarydrugwithpotentialseveremorbidityinhumans AT soleimanimohammad closantelaveterinarydrugwithpotentialseveremorbidityinhumans AT mansourimohammadreza closantelaveterinarydrugwithpotentialseveremorbidityinhumans AT mirshahiahmad closantelaveterinarydrugwithpotentialseveremorbidityinhumans AT inanloubahman closantelaveterinarydrugwithpotentialseveremorbidityinhumans AT abrishamimojtaba closantelaveterinarydrugwithpotentialseveremorbidityinhumans AT pakrahahmadreza closantelaveterinarydrugwithpotentialseveremorbidityinhumans AT masarathamideh closantelaveterinarydrugwithpotentialseveremorbidityinhumans |